(Q48622983)

13 February 2018

https://doi.org/10.1016/j.neuropharm.2021.108876

1 reference

29 December 2023

title

Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice. (English)

1 reference

13 February 2018

1 reference

parkinsonian syndrome

1 reference

Sachin P Patil

1

1 reference

13 February 2018

Pankaj D Jain

2

1 reference

13 February 2018

Jayant S Sancheti

3

1 reference

13 February 2018

Priya J Ghumatkar

4

1 reference

13 February 2018

Rufi Tambe

5

1 reference

13 February 2018

Sadhana Sathaye

6

1 reference

13 February 2018

publication date

31 July 2014

1 reference

13 February 2018

published in

Neuropharmacology

1 reference

13 February 2018

volume

86

1 reference

13 February 2018

page(s)

192-202

1 reference

13 February 2018

Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions

cites work

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Assay of glutathione reductase in crude tissue homogenates using 5,5'-dithiobis(2-nitrobenzoic acid)

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Processing of tumour necrosis factor-α precursor by metalloproteinases

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Flavonoid permeability across an in situ model of the blood-brain barrier

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Improved pyrogallol autoxidation method: a reliable and cheap superoxide-scavenging assay suitable for all antioxidants

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Alterations of oxidative stress markers and apoptosis markers in the striatum after transient focal cerebral ischemia in rats

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Mechanisms of Disease: astrocytes in neurodegenerative disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

The MPTP/probenecid model of progressive Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Polyphenols: food sources and bioavailability

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Inflammation as a causative factor in the aetiology of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Lipid peroxidation: its mechanism, measurement, and significance

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Oxidative stress and the pathogenesis of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Polyphenols: multipotent therapeutic agents in neurodegenerative diseases

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Oxidative stress, mitochondrial dysfunction, and aging

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Protocol for the MPTP mouse model of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Brain-derived neurotrophic factor

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Anti-inflammatory activity of structurally related flavonoids, Apigenin, Luteolin and Fisetin.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Whole animal perfusion fixation for rodents

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Parkinson's disease: clinical features and diagnosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Tyrosine hydroxylase and regulation of dopamine synthesis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Glutathione peroxidase in early and advanced Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Current advances in using neurotrophic factors to treat neurodegenerative disorders

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Colorimetric assay of catalase

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Interaction between flavonoids and the blood-brain barrier: in vitro studies

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Tyrosine hydroxylase-immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson's disease

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Time dependent changes of striatal interneurons after focal cerebral ischemia in rats

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Priorities in Parkinson's disease research

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1016/J.NEUROPHARM.2014.07.012

Identifiers

DOI

10.1016/J.NEUROPHARM.2014.07.012

1 reference

13 February 2018

1 reference

13 February 2018